financetom
Business
financetom
/
Business
/
Draganfly Prices $3.8 Million Offering
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Draganfly Prices $3.8 Million Offering
Nov 19, 2024 9:02 PM

10:59 AM EST, 11/18/2024 (MT Newswires) -- Draganfly ( DPRO ) said Monday it priced an offering of 1.6 million units for gross proceeds of about $3.8 million.

The company agreed to sell 1.6 million units to an unnamed institutional investor for $2.35 apiece. Each unit comprises one common share and one warrant to purchase one share, with each warrant exercisable at CA$3.31 ($2.36) per share.

Draganfly ( DPRO ) said it expects the offering to close Tuesday and plans to use the net proceeds for general corporate purposes.

The company's shares were up 11.5% in recent trading.

Price: 2.61, Change: +0.27, Percent Change: +11.50

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Angi Ordered to Pay $3 Million for Allegedly Misleading Workers About Hourly Rates
Angi Ordered to Pay $3 Million for Allegedly Misleading Workers About Hourly Rates
Jan 7, 2025
02:37 PM EST, 01/07/2025 (MT Newswires) -- Angi ( ANGI ) was ordered by the US District Court for the Southern District of New York to pay roughly $3 million to the Federal Trade Commission for allegedly misleading workers about hourly rates, according to a court filing Tuesday. The complaint filed by the FTC and and the Attorney General of...
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst
Jan 7, 2025
Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. ( AVR ) with a Positive rating and a forecast of $22. The analyst notes that Anteris Technologies’ DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028 Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems...
Cushman & Wakefield, Camden, Blackstone's LivCor Sued by DOJ Over Alleged Rent Pricing Scheme
Cushman & Wakefield, Camden, Blackstone's LivCor Sued by DOJ Over Alleged Rent Pricing Scheme
Jan 7, 2025
02:39 PM EST, 01/07/2025 (MT Newswires) -- Cushman & Wakefield ( CWK ) , Camden Property Trust ( CPT ) , and Blackstone's (BX) LivCor are among the landlords facing a lawsuit filed by the US Department of Justice Tuesday for allegedly participating in an algorithmic pricing scheme. The three landlords along with Greystar Real Estate Partners, Cushman & Wakefield's...
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
Jan 7, 2025
(This Dec. 27 story has been corrected to say Opdivo Qvantig has been approved to treat most previously approved tumor indications, not all previously approved tumor indications, in paragraph 5) By Sneha S K and Sriparna Roy (Reuters) - The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster...
Copyright 2023-2026 - www.financetom.com All Rights Reserved